• Andrew McDonald, Ph.D., CEO

    Dr. McDonald co-founded Attune and has served as CEO since inception. He is also CEO and a Founding Partner of LifeSci Partners, an investor relations and advisory firm specializing in the life sciences. Previously, Dr. McDonald served as senior biotechnology analyst at Great Point Partners and was the Head of Healthcare Research and a Biotechnology Analyst at ThinkEquity Partners. Prior to entering the financial services, Andrew was a senior medicinal chemist Pfizer and Cytokinetics, where he discovered and developed small molecule anti-cancer therapeutics. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.

  • Ira N. Kalfus, M.D., CMO

    Dr. Kalfus was Chief Medical Officer at Thar Pharmaceuticals until its acquisition by Grunenthal in 2016. Dr. Kalfus was previously Vice President of Medical Affairs at Lev Pharmaceuticals, where he led the clinical development for Cinryze, the first HAE prophylaxis therapy, approved by the FDA in 2008. Upon the acquisition of Lev by ViroPharma Inc. in 2008, he consulted on the Cinryze commercial launch and expansion, as well as investor relations activities for ViroPharma which was acquired by Shire in 2013. Dr. Kalfus is consulting Medical Director at RedHill Biopharma Ltd., directing two phase III clinical programs.

    His other positions have included Aetna/US Healthcare (Medical Director), Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement). Dr. Kalfus completed residency in Internal Medicine at Long Island Jewish Medical Center and graduated from Albert Einstein College of Medicine (M.D.) and Columbia University (B.A. in Biology).

  • Jason Bablak, COO

    Jason Bablak was Vice President of Regulatory Affairs at Thar Pharmaceuticals until its acquisition by Grunenthal in 2016. While at Thar, Mr. Bablak was responsible for all regulatory and manufacturing aspects for the development of it lead product candidate, a novel oral compound for the treatment of the orphan pain disease CRPS. Mr. Bablak was previously Vice President of Regulatory Affairs and Product Development at Lev Pharmaceuticals, where, along with Dr. Kalfus, he led the development team for Cinryze, the first FDA approved HAE therapy. Mr. Bablak graduated from the University of Pittsburgh School of Law (J.D.) and Allegheny College (B.S. in Biology).

  • Jennifer Roberts, Clinical Development

    Jennifer Roberts is a Clinical Development Consultant with over 16 years of experience in drug development. Her most recent position before becoming a consultant was Head of Clinical Operations and Program Management at Tokai Pharmaceuticals where she was responsible for the implementation and execution of Clinical Trials for the galeterone program. Prior to joining Tokai, Jennifer led Clinical Operations teams in oncology at Infinity Pharmaceuticals for duvelisib and at Millennium, The Takeda Oncology Company for ADCETRIS. Prior to these positions, Jennifer held management positions at Paratek Pharmaceuticals focusing on infectious disease, Dyax Corporation leading the clinical operations team for Kalbitor (hereditary angioedema) clinical trials that ultimately led to its marketing approval and Children’s Hospital Boston, Dept. of Urology responsible for Sponsor and Investigator initiated clinical studies.

  • Andrew McDonald, Ph.D., CEO

    Dr. McDonald co-founded Attune and has served as CEO since inception. He is also CEO and a Founding Partner of LifeSci Partners, an investor relations and advisory firm specializing in the life sciences. Previously, Dr. McDonald served as senior biotechnology analyst at Great Point Partners and was the Head of Healthcare Research and a Biotechnology Analyst at ThinkEquity Partners. Prior to entering the financial services, Andrew was a senior medicinal chemist Pfizer and Cytokinetics, where he discovered and developed small molecule anti-cancer therapeutics. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.

  • Adam Tomasi, Ph.D.

    Dr. Tomasi is currently Chief Scientific Officer and Head of Corporate Development at ZS Pharma, a member of the AstraZeneca group. He leads regulatory, clinical, and scientific affairs for the development of ZS-9, and prior to the acquisition of ZS Pharma by AstraZeneca in 2015, led investor relations and business development functions. Before joining ZS , Adam was a Principal at Alta Partners, a venture capital firm specializing in investing in development stage therapeutic companies. Dr. Tomasi also served as a senior scientist in early-stage drug discovery with Gilead Sciences and Cytokinetics, where he played a key role in the creation of cardiovascular drug CK-1827452, which is entering phase 3 studies sponsored by Amgen.

    Dr Tomasi gradutated from the Harvard-MIT Biomedical Enterprise Program with an MBA and holds a bachelor’s degree in chemistry from the University of California, Berkeley and a PhD in chemistry from the University of California, Irvine, where he was a Fellow of the American Chemical Society and UC Regents.

  • Coming Soon